术后纵隔复发非小细胞肺癌患者接受同步整合加量挽救性放疗:一项先导研究
该先导研究纳入14例术后纵隔淋巴结复发的非小细胞肺癌患者,接受IMRT-SIB挽救性放疗( elective淋巴结站50Gy/2Gy共25次,宏观淋巴结转移灶加量至62.5Gy/2.5Gy),其中8例(57.1%)同步每周顺铂40 mg/m2。结果5例(35.7%)发生2级肺炎、5例(35.7%)发生2级食管炎,1例3级肺炎经抗生素和激素成功治疗无后遗症;加量体积内局部控制率100%,局部区域控制率79%,中位PFS为7个月;7站淋巴结受累与显著更低的中位无转移生存相关(4个月 vs 未达到,p=0.036)。作者结论认为IMRT-SIB挽救性放疗是可行且耐受良好的治疗选择,更强化放疗方案及联合全身治疗的作用尚待更大队列评估。
要点
- 14例术后纵隔复发NSCLC患者接受IMRT-SIB挽救放疗,8例同步每周顺铂40 mg/m2。
- 2级肺炎和2级食管炎各5例(35.7%),1例3级肺炎经抗生素和激素成功治疗无后遗症。
- 加量体积内局部控制率100%,局部区域控制率79%,中位PFS为7个月。
核心结论
- 作者结论认为,IMRT-SIB挽救性放疗是术后纵隔复发NSCLC可行且耐受良好的治疗选择。
- 作者指出,更强化放疗方案及联合全身治疗的作用尚待在更大队列中评估。
研究设计与样本
- 先导研究,纳入14例术后纵隔淋巴结复发的NSCLC连续患者。
- 放疗方案为25次50Gy/2Gy至 elective淋巴结站,加量至62.5Gy/2.5Gy至宏观淋巴结转移灶。
- 8例(57.1%)患者接受同步每周顺铂40 mg/m2。
主要发现
- 5例(35.7%)患者发生2级肺炎,5例(35.7%)患者发生2级食管炎。
- 1例发生3级肺炎,经抗生素和激素成功治疗,无后遗症。
- 无患者在加量体积内局部复发,局部控制率100%。
- 局部区域控制率79%,3例患者发生淋巴结复发,主要位于 elective体积边缘。
- 7例患者发生远处转移,中位PFS为7个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出更强化放疗方案及联合全身治疗的作用尚待在更大队列中评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of our study was to evaluate feasibility, toxicity profile and local control of salvage intensity modulated radiotherapy (IMRT) delivered with simultaneous integrated boost (SIB) associated or not to concomitant weekly cisplatin in patients affected by NSCLC with mediastinal nodal recurrence after surgery. Patterns of recurrence, outcomes and prognostic factors were assessed. METHODS: Fourteen consecutive patients received 25 fractions of 50Gy/2Gy to the elective nodal stations and boost up to 62.5Gy/2.5Gy to the macroscopic lymph node metastases. Concomitant weekly cisplatin (40 mg/m2) was administered to 8 (57.1%) patients. RESULTS: Five (35.7%) patients experienced grade 2 pneumonitis and 5 (35.7%) patients had grade 2 esophagitis. One case of grade 3 pneumonitis occurred and was successfully treated with antibiotics and steroids with no sequelae. No patient recurred locally in the boost volume (local control 100%). Loco-regional control was 79% with 3 patients that developed nodal recurrence principally marginal to the elective volume. Seven patients developed distant metastases. Median PFS was 7 months. The nodal involvement of station 7 was associated to a significantly lower median metastasis-free survival (4 months vs. not reached, p = 0.036). CONCLUSIONS: Salvage radiotherapy with IMRT-SIB is a feasible and a well-tolerated treatment option for mediastinal recurrent NSCLC after surgery. The role of more intensified radiation regimens and association to systemic therapy remain to be evaluated in larger cohorts.
引用
- Nicosia L, Agolli L, Reverberi C, et al. Salvage radiotherapy with simultaneous integrated boost in non small-cell lung cancer patients with mediastinal relapse after surgery: a pilot study. Radiat Oncol. 2018. PMID: 30352607. doi:10.1186/s13014-018-1155-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。